CD274 and neoplasm: In a study including 22 patients with three tumor types (bladder cancer, NSCLC, or breast cancer) with pre-therapeutic PET/CT with 89Zirconium-labeled atezolizumab (anti-PD-L1), PET uptakes were heterogeneous and generally high in tumors [38].